The approval to advance to Phase 2 of the Acclaim-1 clinical trial indicates progress in the development of REQORSA and Tagrisso combination therapy for advanced non-small cell lung cancer. This progress may be seen as a positive development by investors, potentially leading to an increase in Genprex's stock price.